Skip to content
VuFind
    • English
    • Deutsch
    • Español
    • Français
    • Italiano
    • 日本語
    • Nederlands
    • Português
    • Português (Brasil)
    • 中文(简体)
    • 中文(繁體)
    • Türkçe
    • עברית
    • Gaeilge
    • Cymraeg
    • Ελληνικά
    • Català
    • Euskara
    • Русский
    • Čeština
    • Suomi
    • Svenska
    • polski
    • Dansk
    • slovenščina
    • اللغة العربية
    • বাংলা
    • Galego
    • Tiếng Việt
    • Hrvatski
    • हिंदी
    • Հայերէն
    • Українська
    • Sámegiella
    • Монгол
Advanced
  • (Trial in progress) A real-lif...
  • Cite this
  • Text this
  • Email this
  • Print
  • Export Record
    • Export to RefWorks
    • Export to EndNoteWeb
    • Export to EndNote
  • Permanent link
(Trial in progress) A real-life prospective, observational, post-authorisation safety study in adult breast cancer patients treated with neratinib in extended adjuvant in Europe: the NERLYFE study

(Trial in progress) A real-life prospective, observational, post-authorisation safety study in adult breast cancer patients treated with neratinib in extended adjuvant in Europe: the NERLYFE study

Bibliographic Details
Main Authors: R. Valenti, C. Plantet, A. Tadmouri
Format: Article
Language:English
Published: Elsevier 2021-04-01
Series:Breast
Online Access:http://www.sciencedirect.com/science/article/pii/S0960977621000953
  • Holdings
  • Description
  • Similar Items
  • Staff View
Description
ISSN:1532-3080

Similar Items

  • P009 A real-world prospective observational multi-national study in adult patients with breast cancer treated with extended adjuvant neratinib: NERLYFE study
    by: N. Harbeck, et al.
    Published: (2023-03-01)
  • Neratinib as extended adjuvant therapy in patients with HER2-positive/HR-positive early breast cancer: German HTA-driven analyses from the ExteNET study
    by: D. Lüftner, et al.
    Published: (2021-04-01)
  • Neratinib safety evaluation: real-world adverse event analysis from the FAERS database
    by: Yunhe Fan, et al.
    Published: (2024-09-01)
  • Transcriptome analysis of neratinib treated HER2 positive cancer model vs untreated cancer unravels the molecular mechanism of action of neratinib
    by: Sara Alkhezayem, et al.
    Published: (2020-08-01)
  • Extended adjuvant treatment of patients with HER2+ early breast cancer with neratinib: a multi-centric, prospective, non-interventional study (NIS) in Germany and Austria (ELEANOR)
    by: R. Bartsch, et al.
    Published: (2021-04-01)

Search Options

  • Search History
  • Advanced Search

Find More

  • Browse the Catalog
  • Browse Alphabetically
  • Explore Channels
  • Course Reserves
  • New Items

Need Help?

  • Search Tips
  • Ask a Librarian
  • FAQs